Key features: Investment of up to £8 million in collaborative R&D projects to stimulate the development of regenerative medicines and cell therapies in the UK
Programme: Collaborative research and development
Award: Up to £8m
Opens: 08 Jul 2015, 00:00
Registration closes: 26 Aug 2015, 12:00
Closes: 02 Sep 2015, 12:00
Support phone number: 0300 321 4357
Developing regenerative medicines and cell therapies
Supporting documents & links
Turning promising discoveries into therapies, products, services and sustainable businesses is crucial if the UK is to fulfil its potential in the commercialisation of regenerative medicine and cell therapies. It calls for truly innovative thinking and strong interdisciplinary collaboration, with projects linking to the engineering, manufacture, distribution and supply of potential new treatments. This competition aims to advance the commercial development of regenerative medicines and cell therapies, by supporting a number of projects that together will connect up the research pathway, from early discovery to clinical development and commercial application.
We are looking for projects that address one of the following two streams:
- support for clinical development of novel therapies
- support for development of enabling platform tools and technologies
- preclinical, eg testing for safety and/or efficacy, developing quality control protocols and metrology of identity, purity and potency for particular products
- formulation and delivery, eg incorporating products into delivery devices and scaffolds, delivering product combinations, optimising delivery efficiency
- clinical trials, eg preparing for regulatory submission, preparing clinical plans and embarking on early stage (Phase 1 and 2) clinical studies
- scale-up and manufacturing, eg planning and executing manufacturing of batches for preclinical and clinical studies, overcoming scale-up problems
Stream 2: Particular challenges faced by developers of regenerative medicines and cell therapies include the ability to assess the safety and/or efficacy of therapeutic products, or challenges in being able to develop reproducible and robust manufacturing processes. The focus of projects should therefore be around key platform technologies to address:
- product safety and/or efficacy, eg animal and in vitro models, imaging technologies, biomarker analysis, monitoring
- manufacturing challenges, eg bioprocessing, cell control and differentiation, product characterisation, cell sorting, solutions around formulation and delivery, transportation, storage, tracking, automation
We welcome applications using nascent gene-editing technologies, such as CRISPR-Cas9, to address relevant issues outlined above.
For projects that are closer to the market, we encourage proposals to address broader challenges in advancing the path to commercialisation. These may include proposals to update current practices around regulatory submission and validation, outcome monitoring and assessment, reimbursement and economic modelling, as well as novel business approaches.
Out of scope
In this competition we are not funding projects relating to the discovery of new therapies.
|Competition opens||8 July 2015|
|Competition briefing webinar||16 July 2015|
|Registration deadline||noon 26 August 2015|
|Expressions of interest (EOI) deadline||noon 2 September 2015|
|Stage 2 opens for invited applicants||28 September 2015|
|Deadline for invited applications||4 November 2015|